BEIJING, China, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Pheton Holdings Ltd (the "Company," "we," "our" or "Pheton"), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products and services, today issued the following statements in response to recent market volatility and a third-party publication that has raised questions and concerns among shareholders. Over the past few days, shares of Pheton have experienced an extraordinary and unexpected decline in its share price, which the Company believes may have been triggered by a speculative article published by The Bear Cave on July 29, 2025. The article asserts that Pheton's share price

Coastal States Bank ("CSB" or the "Bank") has announced changes to its senior leadership team. The Bank has appointed Rhonda Thornton as Chief Retail and Experience Officer, unifying its retail operations and branch network across its Lowcountry, Savannah, and Atlanta Regions under her leadership. Rhonda will focus on enhancing the CSB client experience utilizing her expertise in areas such as retail management, customer service, operations, and technology for community, regional, and national banks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250801555532/en/Rhonda Thornton, Chief Retail and Experience Officer, Coastal State

Provides Clear Pathway for Raising Additional Cost-Effective Capital as Mill City Scales Publicly Traded SUI Treasury Mill City Ventures III, Ltd. ("Mill City" or the "Company") (NASDAQ:MCVT) today announced it has entered into an equity line agreement with A.G.P./Alliance Global Partners, as Investor, enabling Mill City to sell up to $500 million of the Company's common stock at the Company's sole discretion, subject to certain restrictions and closing conditions. Any proceeds from the equity line, which included no commitment fee, will be used to further the Company's SUI treasury strategy. Stephen Mackintosh, Chief Investment Officer of Mill City, stated, "This equity line is intende

TAMPA, Fla., Aug. 1, 2025 /PRNewswire/ -- DoubleLine Income Solutions Fund (the "Fund"), which is traded on the New York Stock Exchange under the symbol DSL, this week declared a distribution of $0.11 per share for the month of August 2025. The distributions are subject to the following ex-dividend, record and payment dates set by the Fund's Board of Trustees. August 2025 Declaration Friday, Aug. 1, 2025 Ex-Dividend Wednesday, Aug. 13, 2025 Record Wednesday, Aug. 13, 2025 Payment Friday, Aug. 29, 2025 This press release is not for tax reporting purposes. The press release has

Deutsche Bank downgraded Builders FirstSource from Buy to Hold and set a new price target of $134.00

Lake Street downgraded Clarus Corporation from Buy to Hold and set a new price target of $3.50

Craig Hallum upgraded Protolabs from Hold to Buy and set a new price target of $54.00

Daiwa Securities initiated coverage of MercadoLibre with a rating of Buy and set a new price target of $3,000.00

4 - PEOPLES BANCORP INC (0000318300) (Issuer)

4 - FRANKLIN FINANCIAL SERVICES CORP /PA/ (0000723646) (Issuer)

4 - BREAD FINANCIAL HOLDINGS, INC. (0001101215) (Issuer)

4 - Alpine Income Property Trust, Inc. (0001786117) (Issuer)

4 - NORDSON CORP (0000072331) (Issuer)

4 - NORDSON CORP (0000072331) (Issuer)

4 - PEOPLES BANCORP INC (0000318300) (Issuer)

4 - FRANKLIN FINANCIAL SERVICES CORP /PA/ (0000723646) (Issuer)

6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)

8-K - Allogene Therapeutics, Inc. (0001737287) (Filer)

8-K - Mill City Ventures III, Ltd (0001425355) (Filer)

FWP - JPMORGAN CHASE & CO (0000019617) (Subject)

For Immediate Release: March 28, 2025 Today, the U.S. Food and Drug Administration approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors (neutralizing antibodies).“Today’s approval of Qfitlia is significant for patients wi

For Immediate Release: March 11, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:Today, the FDA published a General Correspondence Letter issued to Mid-Link Technology Testing Co., Ltd. The FDA is vigilant in ensuring data submitted to the FDA can be relied upon to assess the effectiveness, safety, or risk of a device. The FDA has noted an incr

For Immediate Release: February 28, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA approved Odactra to include use in individuals 5 through 11 years of age to treat house dust mite induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis). Odactra is an allergen extract immunotherapy

For Immediate Release: February 21, 2025 Today, the U.S. Food and Drug Administration approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Ctexli is the first FDA-approved drug to treat CTX, a very rare lipid storage disease.“The FDA is dedicated to supporting new drug development for rare diseases including very rare metabolic diseases like cerebrotendinous xanthomato

Coastal States Bank ("CSB" or the "Bank") has announced changes to its senior leadership team. The Bank has appointed Rhonda Thornton as Chief Retail and Experience Officer, unifying its retail operations and branch network across its Lowcountry, Savannah, and Atlanta Regions under her leadership. Rhonda will focus on enhancing the CSB client experience utilizing her expertise in areas such as retail management, customer service, operations, and technology for community, regional, and national banks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250801555532/en/Rhonda Thornton, Chief Retail and Experience Officer, Coastal State

SAN RAFAEL, Calif., Aug. 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced that the company has appointed Ian T. Clark to the company's Board of Directors, effective today, August 1, 2025. Mr. Clark served as Chief Executive Officer of Genentech and a member of the company's Board of Directors from 2010 until his retirement in 2016. Under his leadership, Genentech launched 15 new drugs. Prior to serving as CEO, Mr. Clark held a number of senior management positions at Genentech. Before joining Genentech, Mr. Clark spent 23 years in the biopharmaceuti

ORLANDO, Fla., Aug. 1, 2025 /PRNewswire/ -- The Board of Directors of NNN REIT, Inc. (NYSE:NNN) ("NNN" or the "Company"), a real estate investment trust, today announced that Joshua P. Lewis has been appointed Executive Vice President, Chief Investment Officer. Mr. Lewis is responsible for leading the Company's real estate investments, including structuring, negotiation, and deal execution. Mr. Lewis has held roles of increasing responsibility within the Acquisitions team since joining the Company in 2008 and has served as Senior Vice President, Head of Acquisitions since August 2022. Prior to NNN, Mr. Lewis spent 13 years in the real estate capital markets and investment banking divisions a

HOUSTON, TX, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the appointment of Justin Van Fleet, CPA, as Chief Financial Officer, effective August 1, 2025. Mr. Van Fleet brings more than 20 years of experience in public accounting and assurance services, most recently serving as Partner at Marcum LLP (formerly Friedman LLP). In this role, he led the firm's assurance practice and advised both publicly traded and privately held clients across a wide range of sectors including technology, life sciences, manufacturing, and distribution. He

On July 31, 2025, at its regular quarterly meeting, the Board of Directors of Crawford & Company® (NYSE:CRD) approved an increased quarterly dividend of $0.075 per share on both Class A and Class B Common Stock, up half a cent from the prior quarter. The dividend is payable on August 29, 2025, to shareholders of record as of the close of business on August 15, 2025. About Crawford® Based in Atlanta, Crawford & Company (NYSE:CRD) is a leading global provider of claims management and outsourcing solutions to insurance companies and self‐insured entities with an expansive network serving clients in more than 70 countries. The Company's two classes of stock are substantially identical, exce

Marchex (NASDAQ:MCHX), which harnesses the power of AI and conversational intelligence to drive operational excellence and revenue acceleration, today announced that it will release financial results for the second quarter ended June 30, 2025, on August 12, 2025, at approximately 4:20 p.m. ET. At that time, Marchex will post the press release in the Press Center section of its corporate website (https://www.marchex.com/about-us/press/). Following the release, management will hold a conference call at 5:00 p.m. ET on August 12, 2025, to discuss the results and outlook for the company. A live webcast will be available on the Investors section of the Marchex website (http://investors.marchex

ORINDA, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- MacKenzie Realty Capital, Inc. (NASDAQ:MKZR) ("MacKenzie" or the "Company") today announced that its Board of Directors has approved an effective time at 5:01 p.m. Eastern Standard Time August 4, 2025, for its 1-for-10 reverse stock split. MacKenzie's common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market on August 5, 2025, under the current trading symbol, "MKZR." The reverse stock split was approved by MacKenzie's Board of Directors on July 3, 2025, and is intended to increase the per share trading price of the Company's common stock to enable the Company to meet the minimum bid price requirement

Mogo Inc. (TSX:MOGO) (NASDAQ:MOGO) ("Mogo" or the "Company"), a digital wealth and payments company on a mission to build the future of intelligent finance, today announced it will hold a conference call and webcast to discuss its Q2 2025 financial results on Thursday, August 7, 2025 at 3:00 p.m. ET. The call will be hosted by David Feller, Mogo's Founder & CEO, and Greg Feller, President & CFO. The live webcast will include a slide presentation. The Company will issue its financial results prior to market open on August 7. CONFERENCE CALL DETAILS: DATE: Thursday, August 7, 2025 TIME: 3:00 p.m. (ET) DIAL-IN NUMBER: (289) 514-5100 (Local) or (800) 7

SC 13D/A - ALLIANCEBERNSTEIN HOLDING L.P. (0000825313) (Subject)

SC 13D/A - CVR ENERGY INC (0001376139) (Subject)

SC 13D/A - INCOME OPPORTUNITY REALTY INVESTORS INC /TX/ (0000949961) (Subject)

SC 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)

Recently, on July 4, 2024, a significant insider purchase was recorded at Allied Gaming & Entertainment Inc. as Large owner Choi Roy bought $456,750 worth of shares (360,000 units at $1.27), increasing direct ownership by 14% to 2,871,822 units (SEC Form 4). This purchase is notable for the size of the transaction and the percentage increase in direct ownership, indicating a strong belief in the company's future prospects. Insider purchases are generally viewed positively by investors as they signal confidence from those with intimate knowledge of the company's operations. Examining other recent insider transactions at Allied Gaming & Entertainment Inc., we notice a few patterns worth explo

Recently, on June 25, 2024, Director Romano Kelly A bought $100,051 worth of shares in Athira Pharma Inc. This transaction involved acquiring 42,400 units at $2.36 per share, resulting in a significant increase in direct ownership by 111% to 80,715 units. The purchase was disclosed in the SEC Form 4 filing. Insider buying is often considered a bullish signal as insiders may have insights into the company's future performance. It's essential to analyze this insider purchase in conjunction with previous insider transactions to identify any patterns or trends. Taking into account the information from the SEC filings, several other insiders at Athira Pharma Inc. have also been active in the sto

Recently, on June 26, 2024, Director Juda Scott bought $36,350 worth of shares (5,000 units at $7.27) (SEC Form 4) in INmune Bio Inc. This insider purchase is significant as it indicates confidence from someone within the company towards its future growth prospects. It's interesting to note that this purchase by Juda Scott follows a series of transactions by other insiders in the company. For example, Moss David J bought $149,993 worth of shares (18,028 units at $8.32) on April 24, 2024, increasing direct ownership by 1% to 1,268,179 units. This demonstrates a consistent trend of insider buying within the organization. Looking back at previous transactions, on May 16, 2024, several key ins

Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan